Update from GlobeStar Therapeutics Corporation on recent activity

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

RICHLAND, WA/ACCESSWIRE/August 2, 2022/ GlobeStar Therapeutics Corporation (OTC PINK: GSTC), headquartered in Richland, Wash., is a clinical-stage pharmaceutical company introducing a patented formulation of drugs previously approved for the treatment of multiple sclerosis.

GlobeStar Therapeutics Corporation (GSTC) recently participated in the 29e Annual Race to Erase MS Gala held at the Fairmont Century Plaza in Los Angeles, CA. As a sponsor, GSTC has been placed in a prime position to meet and discuss our proprietary formula with MS influencers, celebrities and doctors who are part of a select network of top MS research centers. MS from the country working to eradicate MS.

MS is a chronic neurodegenerative disease in which the immune system attacks the protective fatty layer (myelin) and causes problems with muscle control, vision, and other bodily functions, which can lead to long-term disability. MS affects more than 800,000 people in the United States and more than 2.58 billion worldwide. The global MS Drugs Market is expected to grow from USD 24.75 billion in 2021 to USD 26.29 billion in 2022 at a compound annual growth rate (CAGR) of 6.2%, and is expected to reach 33.46 billion in 2026 at a CAGR of 6.2%.

During the Gala, we were able to initiate discussions within several organizations to work on the following subjects: PK (pharmacokinetic study), in vitro studies and recruitment of one or more clinical investigators for a first series of IRB (Investigational Review Board) on the efficacy of our proprietary combination of three FDA pre-approved drugs. GSTC is continuing discussions with overseas markets for the same series of studies as well as for manufacturing, sales and distribution.

“We have significantly accelerated our exposure, and with the stunning results from the Italian trials, we believe that in the short term we will be able to move forward with alacrity with these studies. Additionally, I am delighted to report that thanks to ongoing relationships that were the result of contacts at the Gala, that we brought on board two highly desirable and successful agencies to help us tell our compelling story to MS patient advocacy groups as well as hospitals, clinics, etc. .,” said CEO James C. Katzaroff.

Led by Laurie D. Muslow, It’s All Good Entertainment, Inc. has been at the forefront of some of entertainment’s most innovative public relations, marketing and growth campaigns for over 20 years. It’s All Good Entertainment, Inc. is a company where high-caliber presentation and production merge, developing unique campaigns and business solutions. Some of the companies Ms. Muslow has worked for include, but are not limited to: Azoff Entertainment, The Reelz Channel, Clear Channel Radio and TV, Fox Broadcasting/GDLA, BET, My Entertainment, Granada America, The Nederlander Organization, Bitesize TV and NuCalm, to name a few.

It’s All Good Entertainment’s motto is: We want to take all of our customers from Zero to Hero in the least amount of time with the least expense, but NEVER sacrificing quality results.”

Additionally, Laurie introduced us to Animal Farm Creative Agency, which develops and provides comprehensive creative design, production and marketing for some of the world’s largest and most innovative brands. Specializing in investor relations, complex solutions and Fortune 500 CPGs, Animal Farm produces work for film, television, commercial and digital formats.

“I am delighted to work with both groups and anticipate that both companies will meet the highest professional expectations,” said CEO James C. Katzaroff.

“The GlobeStar team has developed something groundbreaking, and it’s going to change the lives of a lot of people,” said Ross Elliot, Creative Director at Animal Farm Creative Agency. Additionally, with our extensive experience working in cutting-edge medical technologies, this is a partnership that we are extremely excited about.”

About GlobeStar Therapeutics

GlobeStar Therapeutics’ mission is to be a biotechnology pioneer in transformative therapies for the management of chronic neurodegenerative diseases. In the initial clinical study (carried out in Italy), the study was composed of 150 volunteers, 90 subjects aged between 25 and 65 years with an evolution of MS from a minimum of 5 to a maximum of 20 years including 60 volunteers healthy. The reading of the trial was based on the Barthel Mobility Index (disability rating) before and after the treatment regimen. The second parameter was the analysis of muscle imbalance using the Kendall scale before and after treatment. Subjects received 2 doses per day for 45 days, along with a controlled diet. 88/150 people had been diagnosed with MSS for ten years or more. 94/150 had an EDSS level above 5.0, 61/150 had an EDSS above 6.5 and 41/150 had an EDSS above 7.5 At the end of the Italian trials, the average EDSS dropped by at least 1.3 points, to reach an average of 5.31 for pretreatment and an average of 4.02 after treatment. After 45 days of treatment, 150/150 reported improved balance and motor control of all limbs, 136/150 reported improved bladder control, 3/150 dropped out for personal reasons. It is important to note that none of the above had an adverse event or new episode of illness.


This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words believes, expects, anticipates or similar expressions. These forward-looking statements involve known and unknown risks and other factors that could cause the company’s actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Also, describing anyone’s past success is not a guarantee of future success. This press release applies as of the date first noted above and the company assumes no responsibility for updating the information included herein for events occurring after the date hereof.


[email protected]

THE SOURCE: GlobeStar Therapeutics Corporation

See the source version on accesswire.com:

Luisa D. Fuller